


2021-22

# ANNUAL REPORT



Foundation for Advancement of  
Essential Diagnostics (FAED)



## Board of Directors

Dr Mustafa Ahmed Barbhuiya – Founder Director  
Anamika Baruah – Director, Administration & Communications  
Dr Amaj Ahmed Laskar – Director

## Registrations

Section 8 Company Registration under Ministry of Corporate Affairs on  
Nov 19, 2018  
R & D License number – 113291  
DIPP Certificate - DIPP78683  
CIN number- U73200AS2018NPL018870  
PAN Card number- AADCF5651Q  
12 A number- AADCF5651QE20214  
80G number- AADCF5651QF20214  
Darpan ID - AS/2021/0298848  
CSR: SRN-T94944113

## Registered Office

House No 11, Latakata Road  
Maidamgaon Bakrapara, Basistha  
Guwahati – 781029  
Assam

## Incubation Centre

Guwahati Biotech Park (GBP), Amingaon  
Guwahati – 781039  
Assam

## Contact

9864295480 (M), 9365061560 (M), 7906299636 (M)  
mabarbhuiya@faed.in, anamika@faed.in, amaj@faed.in  
Website: www.faed.in

## Editorial Team

Anamika Baruah  
Dr. Biswajit Chakraborty

## FAED: An outlook

Foundation for Advancement of Essential Diagnostics, in short, FAED is a Section 8 Company registered under Ministry of Corporate Affairs on Nov 19, 2018. It is a non-profitable company with focus on rendering quality healthcare to all and committed to research and development in the areas of clinical laboratory management, pathology and laboratory medicine. FAED looks towards implementing Essential Diagnostics List (EDL) of World Health Organization (WHO) thereby finding out better and proper and timely diagnosis of health diseases so that patients receive accurate treatment.

## Vision

To provide health care benefits to society to prevent unwanted deaths due to lack of accurate and timely diagnosis. To develop research and continuous medical education (CME) programs that cater to the local community needs and develop comprehensive evidence based 'Essential Diagnostics List' for specific regions in South East Asia.

## Mission

Providing affordable and accessible diagnostic and healthcare services to the people in India and eventually entire south east Asia with the most up-to-date disease diagnostic methods to continually improve the health and well-being of the citizens beyond borders through best practices in laboratory medicine.

## Core Purpose

Provide high quality laboratory medicine services for accurate and timely disease diagnosis to the vast majority of underserved population.


## Core Values

Earnest servitude to better human life and health through the practice of one world one health.

## Big Highly Audacious Goal

Ultimately, as a think-tank and thought-leadership organization, FAED aims to provide the policy and regulatory framework for a strong and functional evidence based laboratory medicine system in south-east Asia to maintain and sustain the quality of high value healthcare delivery following CLIA regulations and ISO medical laboratory standards.

**Company Theme**



## CONTENTS

1. Message from the Director
2. Activities, Projects & Researches
3. The Team
4. Account Statement for the financial year 2021-22

## Message from the Director



The year 2021 started with a positive note with the initiative of Government of India for Covid 19 vaccination. By the mid of the year all the eligible population (above 18 years of age) received vaccination.

Gradually, the Indian population showed sign of herd immunity against SARS CoV-2. Hence, the year looked hopeful and with the lifting up of lockdown in India and the other parts of the world, we heaved a sigh of relief. The situation moved towards normalcy.

On the official front of FAED, Dr. Biswajit Chakraborty was appointed as the Research Scientist and Principal Investigator. With his joining, FAED is all set for boosting up its activities in the days to come by.

FAED carried out its planned activities as well as applied for grants in this year.

I take this opportunity to thank our collaborator, Dibascan Molecular Diagnostic Laboratory, Silchar, our Incubation centre Guwahati Biotech Park, Amingaon all our friends and well-wishers for support and cooperation.

**Anamika Baruah**

*Director, Administration & Communications*  
FAED

## Activities, Projects & Researches

### Official Recruitment

In June 2021, FAED recruited its first employee:  
Dr. Biswajit Chakraborty as a Principal Investigator.



Dr. Biswajit Chakraborty is an experienced Medical Biotechnologist working as a Research Scientist and Principal Investigator at the Foundation for Advancement of Essential Diagnostics (FAED). Dr. Chakraborty specializes in the field of immunology and molecular diagnostics. Dr. Chakraborty earned his PhD in Biotechnology from the Department of Biotechnology, Assam University, Silchar, Assam (2012). His doctoral thesis was mainly based on immunopharmacology, which involves both in-vitro and in-vivo studies.

## COVID-19 Sero-survey

We have initiated clinical laboratory survey during early period of 2020 but it was interrupted due to Covid-19 pandemic lockdown. Dr. Chakraborty took the lead on carrying out the COVID19 survey.

In 2021, we mainly focused on designing and execution different project and apply for grants in different funding agencies. The following projects, which are submitted for grants are;

1) We designed and conducted Covid-19 sero-epidemiological survey in Cachar District of Assam and submitted grant application in ICMR for conducting greater sero-survey in entire Assam. In that project, we are aimed to fulfill the following objective within next 3 years and these are as follows;

- a) A onetime random cross-sectional household-based Covid-19 IgG/IgMsero-survey will be carried out across different age groups and a follow up cohort will be defined.
- b) A onetime random cross-sectional Covid-19 IgG/IgMsero-survey both from 1st and 2nd dose Covid-19 vaccinated people of all 33 districts will be carried out and follow up longitudinal study samples will be selected.
- c) A comparative IgG/IgMsero-positivity data analysis will be carried out among vaccinated and non-vaccinated people of entire Assam.
- d) A statistical analysis of infection rate, susceptibility of infection and herd immunity from IgG/Ig Msero-positivity data will be carried-out for age stratified population of Assam.
- e) Creation of a biorepository of select PBMC and serum samples will be collected from seropositive people for future immune-proteogenomic studies of SARS-CoV-2 infections.





**Picture 3:** Different patient IgG /IgM Rapid antibody testing results

Along with this sero-survey, we will also conduct survey on quality assessment like test type, skill of staff, number of specialized staff etc. of each clinical laboratory of Assam. Basically we will focus on this survey the diagnosis quality of communicable and non-communicable diseases. Based on the need for Assam, this survey will help us to build our greater goal of creating a College of American Pathologist (CAP) accredited Advanced clinical laboratory in Guwahati Biotech park (GBP).

We have also conducted study on method comparison of two IVD kits of Covid-19 antibody on 25 positive patients after a specified period of infection and currently this work is going on. The results of Covid-19 IgG/IgM covid-19 are being collected and will be used to establish the efficacy of the tests.

Projects for infectious diseases diagnostics and point of care

2) We have also submitted grant application to implement mobile clinical laboratory for infectious diseases and there specifically mentioned to implement mobile clinical laboratory for tuberculosis point of care testing. In that project, we are aiming to have following objectives;

- a) Operation of culture free, FDA approved Cepheid MDR-XDR PCR based TB testing facility for Cachar district of Assam augment 8 TB Units and 32 PHCs
- b) Supports DOTS program through our FAED for TB management in Cachar district of Assam
- c) Putting into practice of targeted antibiotic therapy against MDR, XDR and TDR TB in Cachar district of Assam
- d) Implementation of Syndromic testing of multiple infectious pathogen in a single reaction using FDA approved Bio-fire respiratory panel tool.


Successively, we are proposing a long term “FAED Model for Health System and Clinical Laboratory Improvement’ for every district civil hospital in Assam in a public-private partnership model. Our goal is also to replicate it in other states in India that we are pursuing actively.

1. We have started some work on another project on anemia and submitted grant for that project. The project is “Public Health Intervention on Anemia in woman of Kamrup Rural and Cachar District through essential diagnostics tests” and it is having following objectives;

- Health awareness camps will be conducted at local Schools, Temples, Churches and Gurdwaras.
- Anemic parameters will be analyzed by rapid Point of care diagnostic kit HemoCueHb 301 System (Kit). A complete blood count (CBC) by HemoCueHb 301 System (Kit) will be done to evaluate your overall health and detect a wide range of disorders, including anemia, infection and leukemia.
- Analysis of frequency of anemia and assessment of health status followed by conducting health intervention models for maternal health in in woman of Kamrup and Cachar District.



## PROCESS & TECHNOLOGY



FAED Mobile Point of Care Molecular Screening and Diagnostics Lab

### Analytical and clinical performance of two point-of-care detection rapid antibody assays for SARS-CoV-2

Abstract presented at American Association of Clinical Chemistry, Annual Scientific Meeting and Lab expo, 2022; Jul 24-28, Chicago, Illinois, USA.

B. Chakraborty, S. Nath, S. Deb, A. Baruah, P. Bhattacharjee, M. Paul, R. A. Mohan, S. Dutta and M. A. Barbhuiya. Analytical and clinical performance of two point of care rapid antibody assays for SARS-CoV-2.

We have also conducted Covid-19 IgG/IgM sero-epidemiological study in Cachar, Karimganj and Hailakandi districts of Assam. We are currently carrying out the data analysis on over 4000 people sampled in these three districts.

**(A)****(B)****(C)**

In the above pics: (A) A primary health care worker (Mr. Saurav Dev) collecting blood sample in Dibaskan Molecular Diagnostic Laboratory, Silchar, Assam for Covid-19 IgG/IgM Rapid Antibody Test for FAED sero-survey project. (B) Sample application in the lateral flow kit for Covid-19 IgG/IgM Rapid Antibody Test. (C) Nasopharyngeal swab sampling from a patient for COVID-19 Antigen testing.

### **Guwahati Biotech Park**

FAED's incubator, Guwahati Biotech Park (GBP) shifted from the campus of IIT Guwahati to its own campus in Amingaon, Guwahati in Dec, 2021. As such, FAED's office cum laboratory got shifted to GBP, Amingaon.



## The Team



***Dr Mustafa Ahmed Barbhuiya***  
*Founder Director*



***Anamika Baruah***  
*Director,  
Administrations & Communications*



***Dr Amaj Ahmed Laskar***  
*Director*



***Dr Biswajit Chakraborty***  
*Research Scientist & Principal  
Investigator*

## Accounts Statement for the financial year 2021-22

CIN: U73200AS2018NPL018870

## BALANCE SHEET AS AT 31ST MARCH 2022

PARTICULARS	NOTE	AS AT 31-03-2022 (Rs)	AS AT 31-03-2021 (Rs)
<b>I. EQUITY AND LIABILITIES</b>			
<b>(1) Shareholders' Funds</b>			
(a) Share Capital	2.1	-	-
(b) Reserves and Surplus		-	-
(c) Money received against share warrants		-	-
<b>(2) Share application money pending allotment</b>			
<b>(3) Non-Current Liabilities</b>			
(a) Long-term borrowings		-	-
(b) Deferred tax liabilities (Net)		-	-
(c) Other Long term liabilities		-	-
(d) Long-term provisions		-	-
<b>(4) Current Liabilities</b>			
(a) Short-term borrowings	2.2	-	41,000
(b) Trade payables		-	-
(c) Other current liabilities	2.3	61,000	28,500
(d) Short-term provisions		-	-
<b>Total</b>		<b>61,000</b>	<b>69,500</b>
<b>II. ASSETS</b>			
<b>(1) Non-current assets</b>			
<b>(a) Fixed assets</b>			
(i) Tangible assets		-	-
(ii) Intangible assets		-	-
(iii) Capital work-in-progress		-	-
(iv) Intangible assets under development		-	-
(b) Non-current investments		-	-
(c) Deferred tax assets (net)		-	-
(d) Long term loans and advances		-	-
(e) Other non-current assets		-	-
<b>(2) Current assets</b>			
(a) Current investments		-	-
(b) Inventories		-	-
(c) Trade receivables		-	-
(d) Cash and cash equivalents	2.4	61,000	69,500
(e) Short-term loans and advances		-	-
(f) Other current assets		-	-
<b>Total</b>		<b>61,000</b>	<b>69,500</b>

The Schedules referred to above form an integral part of the Balance Sheet.  
In terms of our report of even date annexed.

For SALIL AGARWAL & CO.  
CHARTERED ACCOUNTANTS  
FRN NO: 326763E

SALIL AGARWAL  
(PROPRIETOR)  
Membership No: 067263  
UDIN:-  
GUWAHATI  
THE 1ST DAY OF JUNE, 2022



For and on behalf of the Board

Director  
Foundation for Advancement of  
Essential Diagnostics (FAED)  
Guwahati-781029 (Assam)

MUSTAFA AHMED BARBHUIYA  
DIRECTOR  
DIN: 06465750

ANAMIKA BARUAH  
DIRECTOR  
DIN: 08276501

Director  
Foundation for Advancement of  
Essential Diagnostics (FAED)  
Guwahati-781029 (Assam)



## FOUNDATION FOR ADVANCEMENT OF ESSENTIAL DIAGNOSTICS

CIN: U73200AS2018NPL018870

### PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31ST MARCH 2022

PARTICULARS	NOTE	For The Year Ended 31-03-2022 (Rs)	For The Year Ended 31-03-2021 (Rs)
I. Revenue from operations		-	-
II. Donation received from Members		1,040,199.00	298,800.00
III. <b>Total Revenue (I + II)</b>		<b>1,040,199.00</b>	<b>298,800.00</b>
IV. <u>Expenses:</u>			
Cost of materials consumed		-	-
Purchase of Stock-in-Trade		-	-
Changes in inventories of finished goods, work-in-progress and Stock-in-Trade		-	-
Employee benefit expense		612,000.00	114,000.00
Financial costs		-	-
Depreciation and amortization expense		-	-
Other expenses	2.5	428,199.00	184,800.00
<b>Total Expenses</b>		<b>1,040,199.00</b>	<b>298,800.00</b>
V. Profit before exceptional and extraordinary items and tax (III - IV)		-	-
VI. Exceptional Items		-	-
VII. Profit before extraordinary items and tax (V - VI)		-	-
VIII. Extraordinary Items		-	-
IX. Profit before tax (VII - VIII)		-	-
X. Tax expense:			
(1) Current tax		-	-
(2) Interest on Income Tax/ Service Tax		-	-
XI. Profit/(Loss) from the period from continuing operations (VII - X)		-	-
XII. Profit/(Loss) from discontinuing operations		-	-
XIII. Tax expense of discounting operations		-	-
XIV. Profit/(Loss) from Discontinuing operations (XII - XIII)		-	-
XV. Profit/(Loss) for the period (XI + XIV)		-	-
XVI. Earning per equity share:			
(1) Basic		-	-
(2) Diluted		-	-

In terms of our report of even date annexed

For SALIL AGARWAL & CO.  
CHARTERED ACCOUNTANTS  
FRN NO:326763E

SALIL AGARWAL  
(PROPRIETOR)  
Membership No:067263  
UDIN:-  
GUWAHATI  
THE 1ST DAY OF JUNE, 2022



Director  
Foundation for Advancement of  
Essential Diagnostics (FAED)  
Guwahati-781029 (Assam)

For and on behalf of the Board

*Mustafa Ahmed Barbhuiya*  
MUSTAFA AHMED BARBHUIYA  
DIRECTOR  
DIN: 06465750

*Anamika Baruah*  
ANAMIKA BARUAH  
DIRECTOR  
DIN: 08276501

Director  
Foundation for Advancement of  
Essential Diagnostics (FAED)  
Guwahati-781029 (Assam)

## FOUNDATION FOR ADVANCEMENT OF ESSENTIAL DIAGNOSTICS

CIN: U73200AS2018NPL018870

## NOTES ON ACCOUNTS FOR THE YEAR ENDED MARCH 31, 2022

- a) All the figures have been rounded off to the nearest rupee.  
 b) Previous year figures have been regrouped/ rearranged to make them more comparable with current year figures  
 c) Parties balance are subject to confirmation, reconciliation and final adjustment, if any

## NOTE PARTICULARS

	AS AT 31-03-2022 (Rs)	AS AT 31-03-2021 (Rs)
<b>2.1 Share Capital</b>		
Equity Share Capital		
Authorised Share capital	-	-
Issued, subscribed & fully paid share capital	-	-
<b>Total</b>	<b>-</b>	<b>-</b>

## NOTE PARTICULARS

	AS AT 31-03-2022	AS AT 31-03-2021
<b>2.2 Short Term Borrowings</b>		
Loan From Related Parties	-	41,000.00
<b>Total</b>	<b>-</b>	<b>41,000.00</b>
<b>2.3 Other current liabilities</b>		
Audit fees payable	15,000.00	10,000.00
Salary payable	12,000.00	9,500.00
Rent payable	18,000.00	9,000.00
Accounting Charges	16,000.00	-
<b>Total</b>	<b>61,000.00</b>	<b>28,500.00</b>

For and on behalf of the Board

  
 MUSTAFA AHMED BARBHUIYA  
 DIRECTOR  
 DIN: 06465750

  
 ANAMIKA BARUAH  
 DIRECTOR  
 DIN: 08276501



Director  
 Foundation for Advancement of  
 Essential Diagnostics (FAED)  
 Guwahati-781029 (Assam)

Director  
 Foundation for Advancement of  
 Essential Diagnostics (FAED)  
 Guwahati-781029 (Assam)

## 2.4 Cash and cash equivalents

	(Rs)	(Rs)
Cash in hand	642.14	835.00
Cash at Bank	60,357.86	68,664.60
<b>Total</b>	<b>61,000.00</b>	<b>69,499.60</b>

## 2.5 Other Expenses

Accounting Charges	16,000.00	-
Audit Fee	15,000.00	10,000.00
Rent paid	108,000.00	90,473.00
Website	-	45,884.66
Power and Fuel	300.00	-
Rent for Google space	60,000.00	12,000.00
Travelling and Conveyance	-	1,000.00
Printing & Stationery	15,792.00	2,658.84
Legal charges including ROC charges	16,400.00	22,400.00
Telephone Expenses	4,199.00	-
Bank Charges	247.18	383.50
Round-off	0.26	-
Ghy Biotech Park	55,747.56	-
Project -1	73,038.00	-
Project -2	63,455.00	-
<b>Total</b>	<b>428,199.00</b>	<b>184,800.00</b>

For and on behalf of the Board

  
 MUSTAFA AHMED BARBHUIYA  
 DIRECTOR  
 DIN: 06465750

  
 ANAMIKA BARUAH  
 DIRECTOR  
 DIN: 08276501

Director  
 Foundation for Advancement of  
 Essential Diagnostics (FAED)  
 Guwahati-781029 (Assam)

Director  
 Foundation for Advancement of  
 Essential Diagnostics (FAED)  
 Guwahati-781029 (Assam)





# Foundation for Advancement of Essential Diagnostics (FAED)

Guwahati Biotech Park, Amingaon  
Guwahati -781039  
Assam, India

Phone numbers: 9864295480 (M), 9365061560 (M), 7906299636 (M)  
Email IDs: mabarbhuiya@faed.in, anamika@faed.in, amaj@faed.in  
Website: [www.faed.in](http://www.faed.in)